Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3827 ARTÍCULOS , VIENDO DEL 1501 AL 1515

Use of ramelteon for the treatment of secondary REM sleep behavior disorder

Nomura T, Kawase S, Watanabe Y, Nakashima K.

Intern Med. 2013;52(18):2123-6. doi: 10.2169/internalmedicine.52.9179.

Prospective memory in Parkinson's disease: a meta-analysis

Ramanan S, Kumar D.

J Int Neuropsychol Soc. 2013 Nov;19(10):1109-18. doi: 10.1017/S1355617713001045. Epub 2013 Sep 18.

Low doses of rotigotine in patients with antipsychotic-induced parkinsonism

Di Fabio R, De Filippis S, Cafariello C, Penna L, Marianetti M, Serrao M, Pierelli F.

Clin Neuropharmacol. 2013 Sep-Oct;36(5):162-5. doi: 10.1097/WNF.0b013e3182a2ce3f.

Safety of perioperative treatment with intravenous amantadine in patients with Parkinson disease

Raz A, Lev N, Orbach-Zinger S, Djaldetti R.

Clin Neuropharmacol. 2013 Sep-Oct;36(5):166-9. doi: 10.1097/WNF.0b013e31829bd066.

Impulse control disorder in a patient on long-term treatment with bromocriptine for a macroprolactinoma

Thondam SK, Alusi S, O'Driscoll K, Gilkes CE, Cuthbertson DJ, Daousi C.

Clin Neuropharmacol. 2013 Sep-Oct;36(5):170-2. doi: 10.1097/WNF.0b013e31829fc165.

Prominent psychiatric symptoms in patients with Parkinson's disease and concomitant argyrophilic grain disease

Grau-Rivera O, Gelpi E, Rey MJ, Valldeoriola F, Tolosa E, Compta Y, Martí MJ.

J Neurol. 2013 Dec;260(12):3002-9. doi: 10.1007/s00415-013-7101-1. Epub 2013 Sep 18.

Potential drugs targeting microglia: current knowledge and future prospects

Rangarajan P, Eng-Ang L, Dheen ST.

CNS Neurol Disord Drug Targets. 2013 Sep;12(6):799-806. doi: 10.2174/18715273113126660175.

[Atypical form of tako-tsubo cardiomyopathy in a patient with atrial fibrillation in Wolff-Parkinson-White syndrome complicated with ventricular fibrillation: the diagnostic problems]

Kukla P, Stec S, Karbarz D, Wrzosek B, Jastrzębski M, Kluczewski M, Kurdzielewicz W.

Kardiol Pol. 2013;71(8):864-8. doi: 10.5603/KP.2013.0203.

Understanding cognitive deficits in Parkinson's disease: lessons from preclinical animal models

Solari N, Bonito-Oliva A, Fisone G, Brambilla R.

Learn Mem. 2013 Sep 18;20(10):592-600. doi: 10.1101/lm.032029.113.

Phenotypic screens for compounds that target the cellular pathologies underlying Parkinson's disease

Tardiff DF, Lindquist S.

Drug Discov Today Technol. 2013 Spring;10(1):e121-8. doi: 10.1016/j.ddtec.2012.02.003.

Allosteric modulation of Class C GPCRs: a novel approach for the treatment of CNS disorders

Engers DW, Lindsley CW.

Drug Discov Today Technol. 2013 Summer;10(2):e269-76. doi: 10.1016/j.ddtec.2012.10.007.

Subthalamic neurostimulation for Parkinson's disease with early fluctuations: balancing the risks and benefits

Deuschl G, Agid Y.

Lancet Neurol. 2013 Oct;12(10):1025-34. doi: 10.1016/S1474-4422(13)70151-0.

Effects of tactile biofeedback by a portable voice accumulator on voice sound level in speakers with Parkinson's disease

Schalling E, Gustafsson J, Ternström S, Bulukin Wilén F, Södersten M.

J Voice. 2013 Nov;27(6):729-37. doi: 10.1016/j.jvoice.2013.04.014. Epub 2013 Sep 17.

Subcutaneous apomorphine and non-motor symptoms in Parkinson's disease

Todorova A, Ray Chaudhuri K.

Parkinsonism Relat Disord. 2013 Dec;19(12):1073-8. doi: 10.1016/j.parkreldis.2013.08.012. Epub 2013 Aug 29.

Current status of safinamide for the drug portfolio of Parkinson's disease therapy

Müller T.

Expert Rev Neurother. 2013 Sep;13(9):969-77. doi: 10.1586/14737175.2013.827488.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias